Antiparkinsonian drugs: pharmacological and therapeutic aspects.
D000109:Acetylcholine / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D000661:Amphetamine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000188:drug therapy; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced; D008750:Methyldopa / Q000627:therapeutic use; D009069:Movement Disorders / Q000139:chemically induced; D009638:Norepinephrine / Q000502:physiology; D010276:Parasympatholytics / Q000627:therapeutic use; D012701:Serotonin / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000978:Antiparkinson Agents; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D012701:Serotonin; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D000661:Amphetamine; D002262:Carboxy-Lyases; D001058:Apomorphine; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine